NF-κB, stem cells and breast cancer: The links get stronger

Interdisciplinary Cluster for Applied Genoproteomics (GIGA-Research), Unit of Medical Chemistry and GIGA-Signal Transduction, University of Liege, CHU, Sart-Tilman, 4000 Liège, Belgium.
Breast cancer research: BCR (Impact Factor: 5.49). 07/2011; 13(4):214. DOI: 10.1186/bcr2886
Source: PubMed


Self-renewing breast cancer stem cells are key actors in perpetuating tumour existence and in treatment resistance and relapse. The molecular pathways required for their maintenance are starting to be elucidated. Among them is the transcription factor NF-κB, which is known to play critical roles in cell survival, inflammation and immunity. Recent studies indicate that mammary epithelial NF-κB regulates the self-renewal of breast cancer stem cells in a model of Her2-dependent tumourigenesis. We will describe here the NF-κB-activating pathways that are involved in this process and in which progenitor cells this transcription factor is actually activated.

Full-text preview

Available from: PubMed Central
  • Source
    • "Again, it will be relevant to assess whether this effect is specific for thyroid cancers or it is shared by other tumors that display an enhanced NF-κB activity (e.g. breast cancer, colorectal cancer)[57,58]. In an effort to identify the functional significance of dl922-947-mediated IL-8 and CCL2 reduction, we found that dl922-947 treatment of ATC cells impairs IL- 8-induced angiogenesis and CCL2-induced monocyte chemotaxis in vitro. These findings were substantiated by in vivo results. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human solid tumor and current treatments are ineffective in increasing patients' survival. Thus, the development of new therapeutic approaches for ATC is needed. We have previously shown that the oncolytic adenovirus dl922-947 induces ATC cell death in vitro and tumor regression in vivo. However, the impact of dl922-947 on the pro-tumorigenic ATC microenvironment is still unknown. Since viruses are able to regulate cytokine and chemokine production from infected cells, we sought to investigate whether dl922-947 virotherapy has such effect on ATC cells, thereby modulating ATC microenvironment. dl922-947 decreased IL-8/CXCL8 and MCP-1/CCL2 production by the ATC cell lines 8505-c and BHT101-5. These results correlated with dl922-947-mediated reduction of NF-κB p65 binding to IL8 promoter in 8505-c and BHT101-5 cells and CCL2 promoter in 8505-c cells. IL-8 stimulates cancer cell proliferation, survival and invasion, and also angiogenesis. dl922-947-mediated reduction of IL-8 impaired ATC cell motility in vitro and ATC-induced angiogenesis in vitro and in vivo. We also show that dl922-947-mediated reduction of the monocyte-attracting chemokine CCL2 decreased monocyte chemotaxis in vitro and tumor macrophage density in vivo. Interestingly, dl922-947 treatment induced the switch of tumor macrophages toward a pro-inflammatory M1 phenotype, likely by increasing the expression of the pro-inflammatory cytokine interferon-γ. Altogether, we demonstrate that dl922-947 treatment re-shape the pro-tumorigenic ATC microenvironment by modulating cancer-cell intrinsic factors and the immune response. An in-depth knowledge of dl922-947-mediated effects on ATC microenvironment may help to refine ATC virotherapy in the context of cancer immunotherapy.
    Full-text · Article · Dec 2015 · Oncotarget
    • "Notably, the TIC signature possessed prognostic significance for HCC and other tumors, and exhibited a tight interaction with a variety of key oncogenic and stemness pathways . Among these was a common activation of NF-jB signaling, one of the key-signaling pathway for inflammatory cancers including HCC [11] [12]. Despite some controversies, the frequent up-regulation of NF-jB signaling during chronic liver diseases and hepatocarcinogenesis is well documented [13] [14] and shown to confer survival benefit to cancer cells by protecting them against stress-induced cell death [15] [16] [17] [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The cancer stem cells (CSCs) have important therapeutic implications for multi-resistant cancers including hepatocellular carcinoma (HCC). Among the key pathways frequently activated in liver CSCs is NF-kB signaling. We evaluated the CSCs-depleting potential of NF-kB inhibition in liver cancer achieved by the IKK inhibitor curcumin, RNAi and specific peptide SN50. The effects on CSCs were assessed by analysis of Side Population (SP), sphere formation and tumorigenicity. Molecular changes were determined by RT-qPCR, global gene expression microarray, EMSA, and Western blotting. HCC cell lines exposed to curcumin exhibited differential responses to curcumin and were classified as sensitive and resistant. In sensitive lines, curcumin-mediated induction of cell death was directly related to the extent of NF-kB inhibition. The treatment also led to a selective CSC-depletion as evidenced by a reduced SP size, decreased sphere formation, down-regulation of CSC markers and suppressed tumorigenicity. Similarly, NF-kB inhibition by SN50 and siRNA against p65 suppressed tumor cell growth. In contrast, curcumin-resistant cells displayed a paradoxical increase in proliferation and expression of CSC markers. Mechanistically, an important component of the CSC-depleting activity of curcumin could be attributed to a NF-kB-mediated HDAC inhibition. Co-administration of the class I/II HDAC inhibitor trichostatine sensitized resistant cells to curcumin. Further, integration of a predictive signature of curcumin sensitivity with human HCC database indicated that HCCs with poor prognosis and progenitor features are most likely to benefit from NF-kB inhibition. These results demonstrate that blocking NF-kB can specifically target CSC populations and suggest a potential for combined inhibition of NF-kB and HDAC signaling for treatment of liver cancer patients with poor prognosis. Copyright © 2015. Published by Elsevier B.V.
    No preview · Article · Apr 2015 · Journal of Hepatology
  • Source
    • "Clearly, the NCAM1 expression domain exceeds that of the WT CSC. In this regard, our genomic and proteomic data disclose several specific pathways (e.g., NF-kB, Wnt, PI3K, and mTOR) previously implicated in stemness acquisition (Armstrong et al., 2006; Huang et al., 2012; Katoh and Katoh, 2007; Shostak and Chariot, 2011) as highly operative in WT CSCs. Thus, global analysis not only sheds light on the WT CSC as possessing enhanced stemness alongside a more differentiated renal phenotype but also pinpoints interventions such as mTOR and epidermal growth factor receptor inhibition that may prove beneficial in WT CSC eradication. "
    [Show abstract] [Hide abstract]
    ABSTRACT: An open question remains in cancer stem cell (CSC) biology whether CSCs are by definition at the top of the differentiation hierarchy of the tumor. Wilms' tumor (WT), composed of blastema and differentiated renal elements resembling the nephrogenic zone of the developing kidney, is a valuable model for studying this question because early kidney differentiation is well characterized. WT neural cell adhesion molecule 1-positive (NCAM1(+)) aldehyde dehydrogenase 1-positive (ALDH1(+)) CSCs have been recently isolated and shown to harbor early renal progenitor traits. Herein, by generating pure blastema WT xenografts, composed solely of cells expressing the renal developmental markers SIX2 and NCAM1, we surprisingly show that sorted ALDH1(+) WT CSCs do not correspond to earliest renal stem cells. Rather, gene expression and proteomic comparative analyses disclose a cell type skewed more toward epithelial differentiation than the bulk of the blastema. Thus, WT CSCs are likely to dedifferentiate to propagate WT blastema.
    Full-text · Article · Jul 2014 · Stem Cell Reports
Show more